Ackman's Pershing records big loss on slide of Valeant shares; Chinese pharma plans huge IPO;

@FiercePharma: Roche resolves patent war with India's Glenmark over generic Tarceva. More | Follow @FiercePharma

@EricPFierce: 18 months after the #FDA slapped Cadila with a Form 483, it sends a warning letter. News | Follow @EricPFierce

@CarlyHFierce: ICYMI: Shire could nab Baxalta for $32B this week: Bloomberg. Story | Follow @CarlyHFierce

> Sources say that China's Jiangsu Hansoh Pharmaceutical is planning a Hong Kong IPO that could raise up to $3 billion. Story

> Pershing Square Holdings, one of the funds overseen by investor Bill Ackman, ended the year down 20.5% after its investment in Valeant Pharmaceuticals ($VRX) contracted significantly last year. Story

> A new study has found that shortages of emergency room drugs, many lifesaving, quadrupled in the U.S. between 2001 and 2014. Story

Medical Device News

@FierceMedDev: NIH backs smartphone-based artificial pancreas trials with almost $13M. More | Follow @FierceMedDev

@EmilyWFierce: Pathway Genomics scores $40M in Series E round for genetic test development. Story | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: Scottish researchers develop ingestible 'pill camera' that images non-visible light to detect cancer. More | Follow @VarunSaxena2

> FDA cracks down on transvaginal mesh devices amid safety concerns. More

> Pathway Genomics scores $40M in Series E round for genetic test development. Article

Biotech News

@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Annapurna adds three new gene therapy programs from Ron Crystal's lab at Weill Cornell. Story | Follow @JohnCFierce

@DamianFierce: I cannot prove that OncoCyte got its name from this generator, but I will take credit anyway. Website | Follow @DamianFierce

> Report: Chinese biopharma Jiangsu Hansoh eyes a $3B IPO. Story

> Gilead lines up for a fast FDA OK with its next-gen hep C combo. More

Pharma Manufacturing News

> Cadila to buy Zoetis animal drugs and feed plant in India for $29M. Item

> FDA slaps two Cadila facilities with warning letters. More

> Orchid gets favorable report for its formulation facility near Chennai. Story

> Reuters: J&J shopping its Noramco API unit for up to $800M deal. News

> FDA unveils new pharma manufacturing program as part of draft guidance. More

Drug Delivery News

> Clearside announces positive Phase II results in win for back-of-the-eye drug delivery. Story

> Halozyme picks up $150M credit deal on its Roche, Baxalta royalties. More

> Amgen partners with Unilife on wearable injectors, may buy 20% stake in the struggling company. Article

> UCSB team makes toxic transdermal drugs safer with salt formulation. News

> FDA approves nonalcoholic formulation of cancer drug, eliminating risk of intoxication following treatment. More

Pharma Asia News

> Japan's push on innovative drugs gets a budget boost. More

> India's hep C market sets a global pace on cost, access. Report

> Indonesia pharma investment cap eyed as top firms plan new plants. Story

> Sinovac gets China FDA new drug, production nod for HFMD vaccine. Article

> EU and India set Jan. 18 date for talks on GVK drug ban. Item

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.